93rd European Atherosclerosis Society Congress 2025
Two studies provide insights to PCSK9 adherence
Regular attendance at lipid clinics helps patients adhere to PCSK9 inhibitors, found abstract 049,1 presented at the European Atherosclerosis Society (EAS) Congress, held May 4-7, Glasgow, UK. A second abstract, SaaG100,2 showed baseline statin intolerance to be a key factor reducing PCSK9 adherence. Low adherence…
read more »
PCSK9 inhibitors show best safety profile
In comparison to other lipid lowering agents, PCSK9 inhibitors appear to have the best safety profile for creatine kinase elevation, diabetes, and liver dysfunction. The study, abstract SAAF-097,1 presented at the European Atherosclerosis Society (EAS) Congress, held May 4-7, Glasgow, UK, found bempedoic acid to…
read more »
PCSK9-ANP axis offers new therapeutic target after MI
In a mouse model of MI, PCSK9 deficiency improved ejection fractions and cardiomyocyte contractility, and decreased inflammation and infarct size. The study, abstract 355,1 presented at the European Atherosclerosis Society (EAS) Congress, held May 4-7, Glasgow, UK, also found that atrial natriuretic peptide (ANP) expression…
read more »
Exercise reduces PCSK9 levels following ACS
Patients recovering from acute coronary syndromes (ACS) who undergo regular physical exercise show significant reductions in blood PCSK9 concentrations. The Ukrainian study, abstract 117,1 was presented at the European Atherosclerosis Society (EAS) Congress, held May 4-7, Glasgow, UK. “Reducing PCSK9 levels can improve endothelial function,…
read more »
Pooled analysis demonstrates lerodalcibep reduces MACE
Lerodalcibep, a third generation PCSK9 inhibitor, reduced major adverse cardiovascular events (MACE) by 45 to 50% in a combined pre-defined pooled analysis of three phase 3 studies – LIBerate-HEFH, LIBerate-HR, and LIBerate-CVD (abstract SaaG-008).1 A second pooled analysis (abstract SaaG-117)2 of the studies showed 83…
read more »
